result better revis expect although withdrew
guidanc due manag provid detail region trend
wit well view potenti recoveri think scarciti
valu rel stabil core oper increment opportun tie
test rais pt
compani gave ground-level assess sale trend wit
abt divers busi model busi mix geograph standpoint give
uniqu perspect impact pandem china specif
indic march first two week april seen
steadi improv procedur test volum low seen februari
cardiovascular devic procedur routin core lab test volum first hardest
hit china start earli februari challeng spread part asia europ
late februari last week march affect europ broadli
well base recent data point said start see sign
stabil although rebound notabl compani epd nutrit unit
saw market growth share dynam line histor norm
 pediatr nutrit late march brought increas demand ahead shelter-in-plac
add global sale grew pace growth rate sequenti
script growth expand roll-out libr europ intern
market express confid libr also recent becam first cgm
obtain reimburs japan type diabet balanc see compani
well insul pandem outsid non-diabet medic devic
core diagnost latter import off-set test
detail page
look forward provid outlook break busi segment
two group consumer-bas demand product hospital-bas demand product
consumer-bas demand includ compani epd busi nutrit diabet
perform well compani expect busi continu
deliv solid result throughout although manag note late-march
pantri stock may result modest impact nutrit abt hospital-bas
demand busi like lab cardiovascular neuromod advers affect
chang patient behavior instanc fewer well test widespread
slowdown elect procedur hurt non-diabet devic busi broadli
exclud subseg like heart failur case mostli essenti
expect elective-weight busi difficult quarter
follow recoveri expect base collect data
compani discuss health system ceo obvious eager
resum elect procedur hospit specifi anticip v-
shape recoveri slope right-hand side less steep
left also compani specul
would appropri base look assess prospect
nonetheless referenc pent-up demand cardiovascular core diagnost
support outlook gradual recoveri non-essenti case begin
pleas see page report import disclosur
spin-out proprietari pharma new redux pre-humira
larg diversifi medic product compani competit global franchis
nutrit diagnost medic devic intern brand gener pharmaceut
post-spin ad st jude medic aler busi divest
advanc medic optic unit next five year believ combin abt/stj/
alr busi pois deliv revenu growth ep growth
low mid-teen make standout perform compar medic devic peer
believ may upsid estim potenti out-performance busi
unit better-than-expect contribut stj pipelin product success
business-develop initi blend valuat analysi dcf sum-of-the-part
price-to-earnings support outperform rate expect share outperform market
next month
fda approv libr
decis libr
increas market adopt mitraclip
 roll-out alin
gross oper margin expans
next five year
 enhanc product
acceler diagnost unit
stronger stj synergi captur alr
acceler recoveri intern
hsd revenu mid-dd ep growth
persist emerg market headwind
nutrit
franchis four major health care segment one diversifi
large-cap medic devic compani world offer lead product
nutrit diagnost medic devic establish brand gener pharmaceut
approxim compani revenu gener unit state
anoth come western europ canada japan australia remain
emerg market includ india china russia brazil januari
complet separ proprietari research-bas pharmaceut busi
oper independ large-cap pharmaceut compani
attract test opportun continu expand
follow week launch igg antibodi test discuss
recent report three test two molecular
one antibodi compani addit plan launch igm antibodi test
 near futur note alreadi igm/igg rapid later flow
test avail certain countri outsid allow fast easi test
outsid hospit may come soon manag address
two import issu test thursday call first test avail
potenti suppli shortag stress ship complet test specif
referenc swab face suppli constraint accord check
manag depict greater challeng relat workflow issu area
clearli get attent benefit best practic second respons
question accuraci antibodi test particular
broadli scrutin area manag cite sensit specif rate
respect test administ day symptom
measur differ test test make cross-comparison accuraci
murki instanc test given suffici time seroconvers
data appear extrem competit respect manufactur volum
molecular test compani target combin test per month
monthli lab-bas test point-of-car test although hit per week metric
alreadi estim gross revenu per quarter molecular test
roughli net revenu per quarter anywher
newli launch igg antibodi test expect ship test month april
may scale per month june beyond assum price per test
monthli igg antibodi test could yield addit gross revenu
quarterli cours addit opportun soon-to-launch igm
signific disrupt major pipelin project
recent receiv ce mark approv product key area cardiovascular
includ triclip tendyn next-gener gallant ask specif
 regulatori disrupt due primarili would affect libr
mitraclip ncd compani acknowledg modest timelin slippag
experienc date said think delay hold back busi
either product separ respond question whether
would use balanc sheet strength make opportunist acquisit time
target-compani valuat could depress stress belief suffici
opportun exist portfolio along increment benefit
test still develop manag express confid outlook said
primarili need focu execut
revenu total vs street forecast result reflect revenu
growth report basi organ basi organ growth
perform better project recent revis number
lower pose challeng particularli non-diabet medic
devic core diagnost compani offset diabet nutrit epd
well test nutrit sale ahead street consensu
repres organ growth establish pharma also saw strong
sale beat consensu estim organ growth
diagnost sale top street target reflect organ growth
medic devic sale organ basi came higher
end estim street rang incom
statement adjust gross margin approxim bp year
year lastli adjust ep better estim street
consensu although clearli benefit reduc expect head
quarterli report still view result reason encourag better
perform mani medic devic peer
rais price use forward year
follow abt report januari ep estim
respect forecast stand
respect reflect neg impact pandem particularli
year continu believ better much better posit mani
med tech peer given stabil outsid non-diabet medic devic core
diagnost uniqu opportun leader test think
compani scarciti valu current environ wed also argu
look repres normal busi period weve
model transit year compani still rebound toward former
growth trajectori weve therefor use forward year valuat
maintain prior valuat multipl includ forward-year price-to-earnings multipl
new price target previous base averag price-to-
earn discount cash flow sum-of-the-part valuat approach
compani report thomson eikon cowen compani
consensu chg establish lab molecular poc medic good gross gross margin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper dilut share estimatesactu cowen
compani report thomson eikon cowen compani
consensu chg pharma nutrit ww nutrit ww nutrit ww cardiovascular neuromodul ww rhythm manag ww electrophysiolog ww heart failur ww vascular ww structur heart ww neuromodul ww ww diagnost ww diagnost ww diagnost ww actualsour estim cowen
compani report thomson eikon cowen compani
good gross gross margin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper restructur non-recur charg dilut share analysisgross end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
laboratori diagnost laboratori diagnost molecular diagnost point diagnost point diabet revenu rhythm manag heart failur rhythm manag heart cardiovascular structur heart cardiovascular structur revenu end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
adjust good adjust gross adjust gross oper incom oper incom interest expens interest net interest expens currenc hedg loss expens net expens pre-tax incom incom tax incom tax net incom adj net incom oper net incom oper ep continu oper ep discontinu oper changeadjust ep oper includ disc ep oper share analysisgross incom -oper cowen
compani report thomson eikon cowen compani
 exclud ww sale exclud pharma exclud exclud ww sale exclud devic rhythm manag heart failur exclud ww rhythm manag heart ww sale exclud cardiovascular structur heart exclud ww ww sale exclud neuromodul exclud ww ww sale exclud neuromodul exclud ww stj ww sale exclud diabet exclud ww diabet ww sale exclud devic exclud ww medic ww sale exclud revenu exclud ww ww sale exclud total revenu exclud ww sale exclud cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
risk includ stj alr integr global competit pressur adult
pediatr nutrit busi price pressur procedur volum pressur
stent busi vascular product regulatori time approv mitraclip
 risk time regulatori approv meet demand
hundr product launch emerg market establish pharmaceut
busi meet growth target develop emerg market
meet target margin improv four major segment
